PortalPublikationenThe graft versus leukemia response after allogeneic hematopo...

The graft versus leukemia response after allogeneic hematopoietic stem cell transplantation

Standard

The graft versus leukemia response after allogeneic hematopoietic stem cell transplantation. / Riddell, Stanley R; Berger, Carolina; Murata, Makoto; Randolph, Sophia; Warren, Edus H.

in: BLOOD REV, Jahrgang 17, Nr. 3, 09.2003, S. 153-62.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung

Harvard

Riddell, SR, Berger, C, Murata, M, Randolph, S & Warren, EH 2003, 'The graft versus leukemia response after allogeneic hematopoietic stem cell transplantation', BLOOD REV, Jg. 17, Nr. 3, S. 153-62. https://doi.org/10.1016/s0268-960x(03)00007-9

APA

Riddell, S. R., Berger, C., Murata, M., Randolph, S., & Warren, E. H. (2003). The graft versus leukemia response after allogeneic hematopoietic stem cell transplantation. BLOOD REV, 17(3), 153-62. https://doi.org/10.1016/s0268-960x(03)00007-9

Vancouver

Riddell SR, Berger C, Murata M, Randolph S, Warren EH. The graft versus leukemia response after allogeneic hematopoietic stem cell transplantation. BLOOD REV. 2003 Sep;17(3):153-62. https://doi.org/10.1016/s0268-960x(03)00007-9

Bibtex

@article{4923892a767c404c927a2be98164331b,
title = "The graft versus leukemia response after allogeneic hematopoietic stem cell transplantation",
abstract = "It is now well established that the efficacy of allogeneic hematopoietic stem cell transplant for eradicating a variety of hematologic malignancies is related to antitumor activity mediated by donor immune cells contained in the stem cell graft. Recent studies have provided fundamental insights into the nature of the effector cells and target molecules that are responsible for the graft versus tumor effect. T cells specific for minor histocompatibility antigens can mediate potent antitumor activity but are also responsible for graft versus host disease (GVHD). The molecular characterization of minor antigens has suggested ways of potentially separating antitumor activity from GVHD. The challenge for the future is to continue to build on our understanding of the allogeneic graft versus tumor effect and develop strategies that can be incorporated into clinical practice to augment this effect without GVHD.",
keywords = "Animals, CD8-Positive T-Lymphocytes/immunology, Graft vs Host Disease/immunology, Graft vs Leukemia Effect/immunology, Hematopoietic Stem Cell Transplantation, Humans, Minor Histocompatibility Antigens/immunology, Models, Immunological, T-Lymphocytes/immunology, Transplantation, Homologous",
author = "Riddell, {Stanley R} and Carolina Berger and Makoto Murata and Sophia Randolph and Warren, {Edus H}",
year = "2003",
month = sep,
doi = "10.1016/s0268-960x(03)00007-9",
language = "English",
volume = "17",
pages = "153--62",
journal = "BLOOD REV",
issn = "0268-960X",
publisher = "Churchill Livingstone",
number = "3",

}

RIS

TY - JOUR

T1 - The graft versus leukemia response after allogeneic hematopoietic stem cell transplantation

AU - Riddell, Stanley R

AU - Berger, Carolina

AU - Murata, Makoto

AU - Randolph, Sophia

AU - Warren, Edus H

PY - 2003/9

Y1 - 2003/9

N2 - It is now well established that the efficacy of allogeneic hematopoietic stem cell transplant for eradicating a variety of hematologic malignancies is related to antitumor activity mediated by donor immune cells contained in the stem cell graft. Recent studies have provided fundamental insights into the nature of the effector cells and target molecules that are responsible for the graft versus tumor effect. T cells specific for minor histocompatibility antigens can mediate potent antitumor activity but are also responsible for graft versus host disease (GVHD). The molecular characterization of minor antigens has suggested ways of potentially separating antitumor activity from GVHD. The challenge for the future is to continue to build on our understanding of the allogeneic graft versus tumor effect and develop strategies that can be incorporated into clinical practice to augment this effect without GVHD.

AB - It is now well established that the efficacy of allogeneic hematopoietic stem cell transplant for eradicating a variety of hematologic malignancies is related to antitumor activity mediated by donor immune cells contained in the stem cell graft. Recent studies have provided fundamental insights into the nature of the effector cells and target molecules that are responsible for the graft versus tumor effect. T cells specific for minor histocompatibility antigens can mediate potent antitumor activity but are also responsible for graft versus host disease (GVHD). The molecular characterization of minor antigens has suggested ways of potentially separating antitumor activity from GVHD. The challenge for the future is to continue to build on our understanding of the allogeneic graft versus tumor effect and develop strategies that can be incorporated into clinical practice to augment this effect without GVHD.

KW - Animals

KW - CD8-Positive T-Lymphocytes/immunology

KW - Graft vs Host Disease/immunology

KW - Graft vs Leukemia Effect/immunology

KW - Hematopoietic Stem Cell Transplantation

KW - Humans

KW - Minor Histocompatibility Antigens/immunology

KW - Models, Immunological

KW - T-Lymphocytes/immunology

KW - Transplantation, Homologous

U2 - 10.1016/s0268-960x(03)00007-9

DO - 10.1016/s0268-960x(03)00007-9

M3 - SCORING: Review article

C2 - 12818225

VL - 17

SP - 153

EP - 162

JO - BLOOD REV

JF - BLOOD REV

SN - 0268-960X

IS - 3

ER -